Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | NAAA | Q02083 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158848 | 1.00 | KMT2A (0.57) | KMT2AMEN1NAAAMMP8GAA | |
| SCHEMBL4158947 | 1.00 | KMT2A (0.57) | KMT2AMEN1NAAAMMP8GAA | |
| Benzoic Acid SCHEMBL9503440 | 0.92 | KMT2A (0.55) | KMT2AMEN1NAAAMMP8LMNA | |
| SCHEMBL18134733 | 0.89 | KMT2A (0.66) | KMT2AMEN1NAAAPOLBPKM | |
| SCHEMBL10693686 | 0.89 | ALDH1A1 (0.56) | KMT2AMEN1POLBLMNA | |
| SCHEMBL30132781 | 0.89 | MALT1 (0.55) | KMT2AMEN1LMNA | |
| SCHEMBL9501925 | 0.89 | MEN1 (0.75) | KMT2AMEN1NAAAPKMTP53 | |
| SCHEMBL9502670 | 0.89 | MALT1 (0.55) | KMT2AMEN1LMNA | |
| SCHEMBL29521788 | 0.89 | ALDH1A1 (0.56) | KMT2AMEN1POLBLMNA | |
| SCHEMBL18134713 | 0.89 | ALDH1A1 (0.56) | KMT2AMEN1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0376852-B1 | MICROGRANULES ESSENTIALLY CONSISTING OF TRIGLYCERIDES OF SATURATED FATTY ACIDS LOADED WITH AN ACTIVE SUBSTANCE, AND THEIR TOPICAL THERAPEUTICAL USE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-06-23 | — | — | EP | claimed |
| EP-0376852-A1 | Microgranules essentially consisting of triglycerides of saturated fatty acids loaded with an active substance, and their topical therapeutical use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-07-04 | — | — | EP | claimed |
| EP-0098743-B1 | PHENYL ALPHA-ACYLOXYACETAMIDE DERIVATES AND THEIR THERAPEUTIC USE | Yu, Ruey J., Dr. (US) | 1988-09-28 | — | — | EP | claimed |
| US-11180748-B2 | Reagents and methods for esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200032238-A1 | Reagents and Methods for Esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-01-30 | — | — | US | disclosed |
| US-10428323-B2 | Reagents and methods for esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180037881-A1 | Reagents and Methods for Esterification | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-9790483-B2 | Reagents and methods for esterification | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160297752-A1 | REAGENTS AND METHODS FOR ESTERIFICATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-13 | — | — | US | disclosed |
| WO-2016164622-A1 | REAGENTS AND METHODS FOR ESTERIFICATION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20090311318-A1 | SUBSTITUTED (S)-BENZOXAZINONES | P&H THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| EP-0376852-B1 | MICROGRANULES ESSENTIALLY CONSISTING OF TRIGLYCERIDES OF SATURATED FATTY ACIDS LOADED WITH AN ACTIVE SUBSTANCE, AND THEIR TOPICAL THERAPEUTICAL USE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-06-23 | — | — | EP | disclosed |
| US-5128488-A | Phosphorus-metal complex catalyst | SOCIETE CHIMIQUE DES CHARBONNAGES S.A. (FR) | 1992-07-07 | — | — | US | disclosed |
| EP-0463962-A1 | Preparation of fatty product microspheres loaded or not with an active substance | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1992-01-02 | — | — | EP | disclosed |
| EP-0443923-A1 | New aminophosphine-phosphinites, their process and their use for enantio-selective reactions | SANOFI (FR) | 1991-08-28 | — | — | EP | disclosed |
| EP-0320096-B1 | PROCESS FOR ASYMMETRICALLY REDUCING CARBONYL COMPOUNDS | AJINOMOTO CO., INC. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4943652-A | Process for asymmetrically reducing carbonyl compounds | AJINOMOTO CO., INC. (JP) | 1990-07-24 | — | — | US | disclosed |
| EP-0376852-A1 | Microgranules essentially consisting of triglycerides of saturated fatty acids loaded with an active substance, and their topical therapeutical use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-07-04 | — | — | EP | disclosed |
| EP-0320096-A1 | Process for asymmetrically reducing carbonyl compounds | AJINOMOTO CO., INC. (JP) | 1989-06-14 | — | — | EP | disclosed |
| WO-1987007889-A1 | ASYMETRIC HYDROGENATION PROCESS FOR CARBONYL COMPOUNDS, AND COMPOUNDS OBTAINED | SOCIETE CHIMIQUE DES CHARBONNAGES S.A. (FR) | 1987-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180748-B2 | Reagents and methods for esterification | VIP, BCR, TMPO | KMT2A 4234/4885MEN1 1213/4885NAAA 566/4885 |
| US-10428323-B2 | Reagents and methods for esterification | VIP, BCR, TMPO | KMT2A 4430/4885MEN1 1231/4885NAAA 639/4885 |
| US-20180037881-A1 | Reagents and Methods for Esterification | VIP, BCR, TMPO | KMT2A 4430/4885MEN1 1231/4885NAAA 639/4885 |
| US-20160297752-A1 | REAGENTS AND METHODS FOR ESTERIFICATION | VIP, BCR, TMPO | KMT2A 4430/4885MEN1 1231/4885NAAA 639/4885 |
| US-20200032238-A1 | Reagents and Methods for Esterification | VIP, BCR, TMPO | KMT2A 4234/4885MEN1 1213/4885NAAA 566/4885 |
| US-20090311318-A1 | SUBSTITUTED (S)-BENZOXAZINONES | REN, ACE, AGTR1 | KMT2A 4044/4885MEN1 3604/4885NAAA 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.